Perimenopause lab panel: the markers that finally make the chaos legible
Anchor biomarkers: FSH, estradiol, progesterone, AMH
TL;DR
- •Perimenopause is not one number — it's a moving target across multiple hormones. FSH, estradiol, progesterone, and AMH each tell part of the story, and interpretation depends heavily on cycle day.
- •A single blood draw is often misleading. Hormones fluctuate dramatically week to week in perimenopause; trajectory across multiple panels tells the truth.
- •The most useful conversation isn't "are you in perimenopause" — it's "what specific patterns are driving your symptoms, and what can we do about them?"
What each marker tells you
| Marker | Reference range | What it means |
|---|---|---|
| FSH | < 10 mIU/mL (follicular phase) · > 25 mIU/mL postmenopausal | Rises as ovarian reserve declines. Persistently elevated FSH suggests late perimenopause or menopause. |
| LH | 5 – 20 mIU/mL (cycle-dependent) | Companion to FSH; the ratio shifts in late perimenopause. |
| Estradiol | varies wildly by cycle phase; 30 – 400 pg/mL | The dominant reproductive estrogen. In perimenopause it doesn't simply decline — it *fluctuates* wildly, often spiking very high before dropping. |
| Progesterone (luteal phase) | > 10 ng/mL in ovulatory cycle | The "calming" hormone. Drops earlier in perimenopause than estradiol does. The progesterone deficit drives many perimenopause symptoms (sleep, mood, heavy bleeding). |
| AMH (anti-Müllerian hormone) | 1.0 – 3.5 ng/mL reproductive · < 0.5 declining reserve | Reflects remaining ovarian follicle pool. The most stable marker — doesn't fluctuate with cycle. |
| TSH + free T4 | normal | Thyroid dysfunction mimics or worsens perimenopause symptoms. |
| Testosterone (total + free) | 8 – 60 ng/dL (total) | Drops 50% from age 20 to 40 in many women. Contributes to libido and energy changes. |
| DHEA-S | 65 – 380 µg/dL | Adrenal androgen; declines with age. |
| Cortisol (AM) | 6 – 23 µg/dL | Stress and sleep disruption in perimenopause often shift cortisol patterns. |
| Vitamin D, B12, ferritin | adequate | Often suboptimal; symptom overlap is real. |
| Lipid panel + fasting insulin | optimal | Cardiovascular and metabolic risk accelerates in perimenopause/menopause. |
Three real patterns Phi has seen
Example patterns · synthetic data drawn from Phi's scenario library. Not real patient records.
Pattern 1 — Early perimenopause with progesterone deficit.
Age 43. Cycles still regular but shorter (24–26 days). FSH 9 (normal). Estradiol 240 (high-normal). Luteal progesterone 6.8 (low). AMH 1.2 (declining). The "labs are normal" reading misses the progesterone deficit, which often shows up first — driving sleep disruption, irritability, heavier or shorter cycles, and breast tenderness. This is the moment when targeted progesterone support (lifestyle + sometimes cyclic micronized progesterone) can make a substantial symptom difference, well before any "menopause" diagnosis would apply.
Example pattern · synthetic data
Pattern 2 — Late perimenopause with estrogen swings.
Age 48. Cycles unpredictable (30–60 days). FSH varies (28 → 9 → 22 across recent panels). Estradiol fluctuates wildly (450 → 65 → 280 across same panels). Hot flashes, sleep disruption, mood lability, occasional skipped cycles. The trajectory is the diagnosis: highly variable hormones with overall trend toward elevated FSH. The interpretation hinges on the pattern across time, not any single draw.
Example pattern · synthetic data
Pattern 3 — Postmenopausal stabilization on hormone therapy.
Age 53. No cycles for 14 months. Off HT: FSH 78, estradiol < 15, progesterone < 0.2. On low-dose transdermal estradiol + cyclic micronized progesterone: estradiol 65 (target range), well-tolerated, no breakthrough bleeding, symptom resolution on hot flashes / sleep / mood. The labs become useful for *monitoring* therapy adequacy and for cardiovascular and bone-health baselines, not for diagnosis at this point.
Example pattern · synthetic data
Questions to bring to your doctor
- Given my symptoms, can we run a *full* panel (FSH, LH, estradiol, progesterone, AMH) — not just FSH?
- If I'm still cycling, can we time the panel to a specific cycle day for interpretability (e.g., day 3 for FSH/AMH, day 21 for progesterone)?
- Have we ruled out thyroid dysfunction, low iron, low vitamin D, and low B12 — all of which mimic or worsen perimenopause?
- What's my cardiovascular and metabolic baseline now, as estrogen's protective effects start to wane?
- What's your perspective on hormone therapy for my specific situation, given current cardiovascular and breast-cancer risk data?
- Are there evidence-based non-hormonal options for the symptoms bothering me most (vasomotor, sleep, mood, vaginal/urinary)?
- Should I be tracking symptoms or labs longitudinally to make sure interventions are actually helping?
What Phi adds beyond a single number
Perimenopause is the textbook example of why single-snapshot labs fail. Hormones move week to week; symptoms move day to day; interventions work over months. Phi reads every panel you upload, tracks the trajectory across FSH, estradiol, progesterone, AMH (and the thyroid, metabolic, and nutrient markers that confound interpretation), and helps surface what's actually moving and what isn't. The integrated picture lets you and your provider have a real conversation about timing, options, and trajectories — not just react to whichever number happened to be drawn today.
Upload your most recent lab report. Phi will pull out every perimenopause-relevant marker, compare them against optimal (not just reference) ranges, flag the pattern, and tell you what to ask at your next appointment.
Frequently asked questions
At what age does perimenopause start?
Typically 40–47, but can begin as early as the late 30s. Average duration is 4–8 years before menopause (defined as 12 consecutive months without menstruation). Substantial individual variation.
Can I be in perimenopause if I still have regular periods?
Yes — frequently. Hormonal changes often begin years before cycle changes become obvious. Cycle shortening (to 24–26 days), heavier or lighter bleeding, sleep changes, mood shifts, and night sweats can all start with regular cycles still intact.
Is hormone therapy safe?
The data has shifted significantly since the 2002 Women's Health Initiative scared a generation of women off HT. Current evidence: modern transdermal estradiol + micronized progesterone, started in the 50s near menopause, has a favorable risk-benefit profile for most women with bothersome symptoms — particularly for cardiovascular health and bone health. Individual risk depends on personal and family history. Worth a thorough conversation with a perimenopause-knowledgeable provider.
Will my symptoms just resolve when I hit menopause?
Some will (cycle chaos, of course; many vasomotor symptoms gradually subside over years). Others may persist or worsen — vaginal/urinary symptoms typically progress without treatment; bone loss accelerates; cardiovascular risk increases. "Just waiting it out" is a real option for some symptoms but a poor one for others.
Are bioidentical hormones better than synthetic?
"Bioidentical" simply means molecularly identical to what your body makes (e.g., estradiol vs. conjugated equine estrogens; micronized progesterone vs. medroxyprogesterone acetate). The current preference for transdermal estradiol + oral micronized progesterone in many modern HT protocols is largely about safety (lower venous-thrombosis risk than oral estradiol; better symptom profile than synthetic progestins). It's not about "natural vs. unnatural" — it's about specific molecular profiles with different risk-benefit data.
Why do I feel like I'm losing my mind?
Estrogen affects neurotransmitter systems involved in mood and cognition. Progesterone deficit affects sleep. Sleep deprivation affects everything. The cognitive, mood, and "brain fog" experiences of perimenopause are real, well-documented, and not "just stress" — though stress amplifies them. Treatment options (hormonal and non-hormonal) exist and are worth pursuing.
What about supplements — black cohosh, evening primrose, etc.?
The evidence base is uneven. Black cohosh has modest data for vasomotor symptoms. Evening primrose is largely unsupported. Phytoestrogens (soy isoflavones) have mixed data. Most over-the-counter "menopause" supplements lack rigorous evidence. The 2023 NAMS Nonhormone Therapy Position Statement (see references) reviews supplements/herbal remedies and finds insufficient evidence to recommend them. Discuss any supplement with your provider — many interact with medications or have their own risk profiles.
References
All citations verified against PubMed / publisher of record 2026-05-25.
- 1."The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 29(7):767-794. — Current NAMS standard for hormone-therapy decision-making in perimenopause / menopause. Basis for the "transdermal estradiol + micronized progesterone is favorable for most healthy symptomatic women under 60 or within 10 years of menopause onset" framing.PubMed →DOI →
- 2.Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 19(4):387-395. — STRAW+10: current gold-standard staging system for reproductive aging through menopause (cycle changes + FSH + AMH + antral follicle count). Basis for the perimenopause staging on this page.PubMed →DOI →
- 3.Manson JE, Aragaki AK, Rossouw JE, et al. (WHI Investigators). (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 318(10):927-938. — Long-term WHI follow-up showing no overall mortality difference for HT vs placebo across 18 years; favorable benefit-risk ratio for women initiating HT within 10 years of menopause. Basis for the "modern view of HT safety" framing.PubMed →DOI →
- 4."The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 30(6):573-590. — Current NAMS standard for nonhormone vasomotor-symptom management: recommends CBT, hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I); does not recommend supplements/herbal remedies, soy, paced respiration. Basis for the supplements-evidence framing in the FAQ.PubMed →DOI →
Every link above opens the PubMed abstract or publisher's DOI landing page in a new tab. All citations verified vs PubMed / publisher of record 2026-05-26.
By Steve Pinedo
Co-founder, Phi Longevity
Last updated: 2026-05-26
Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi →